sofosbuvir (Sovaldi®)


Indications for Prior Authorization:

  • Treatment of chronic hepatitis C (CHC), genotype 1, 2, 3, or 4 as a component of a combination antiviral treatment regimen.

All of the following must be met as a condition for coverage:

  • Must not be used as monotherapy
  • Must have compensated liver disease by ultrasound or biopsy, stating F2, F3 or F4 fibrosis.
  • Resistance testing must be included with the prior authorization request for genotypes 1 and 3.
    • Treatment failure associated with HCV resistance to newly developed direct-acting antiviral agents is not an uncommon occurrence and poses a substantial problem to clinicians trying to re-treat patients who have failed available interferon-free treatments.
  • Documentation of intolerance to interferon alfa if applicable (see below).
  • Trial and failure of preferred agent(s) Epclusa, Harvoni, Vosevi

This Medication is Not Approvable for the following condition(s).

  • Any condition not listed above as an approved indication

Dosing and Duration of Therapy:

Genotype 1

  • Patients who can receive interferon:  400 mg once daily + peginterferon alfa + ribavirin, 12 weeks
  • Patients who cannot receive interferon:  400mg once daily + ribavirin, 24 weeks.

Genotype 2               

  • sofosbuvir 400 mg once daily + ribavirin, 12 weeks

Genotype 3               

  • sofosbuvir 400 mg once daily + ribavirin, 24 weeks

Genotype 4 

  • sofosbuvir 400 mg once daily + peginterferon alfa + ribavirin, 12 weeks.

Hepatocellular carcinoma awaiting liver transplantation

  • Should be used in combination with ribavirin for treatment of CHC in patients with hepatocellular carcinoma awaiting liver transplantation for up to 48 weeks or until liver transplantation, whichever occurs first

Intolerance to interferon alfa with documentation of one of the following:

  • Chart note documentation of intolerance to previous trial of interferon (treatment failure is not a contraindication)
  • Autoimmune hepatitis
  • History of depression
  • Baseline neutrophil count < 1,500 cells/ul, platelet count < 90,000 cells/ul or hemoglobin < 10 g/dL
  • Pre-existing cardiac disease


Last review date: September 12, 2018

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar